Tratamiento de la hepatitis crónica por virus C

作者: Agustín Albillos Martínez , José Luis Martínez Porras , José Luis Calleja Panero

DOI:

关键词:

摘要: A B S T R C The Hepatitis virus is the leading cause of chronic liver disease, cirrhosis, hepatocellular carcinoma and first transplantation in Western countries. broad clinical spectrum disease ranges from acute hepatitis with spontaneous seroconversion until cirrhosis. High rate chronicity present. Effective therapies are thus required to prevent progression. Several viral host factor play an important role progression therapeutic success. current initial treatment choice combination therapy alpha interferon ribavirin, although still unsatisfactory. New schedules raising improve efficacy greatly.

参考文章(19)
Thierry Poynard, John McHutchison, Zachary Goodman, Mei-Hsiu Ling, Janice Albrecht, Is an “à la carte” combination interferon alfa‐2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology. ,vol. 31, pp. 211- 218 ,(2000) , 10.1002/HEP.510310131
F. Bonino, f. Oliveri, P. Colombatto, B. Coco, D. Mura, G. Realdi, M.R. Brunetto, Treatment of patients with chronic hepatitis C and cirrhosis Journal of Hepatology. ,vol. 31, pp. 197- 200 ,(1999) , 10.1016/S0168-8278(99)80401-2
William G Bennett, Yuji Inoue, J Robert Beck, John B Wong, Stephen G Pauker, Gary L Davis, Estimates of the Cost-Effectiveness of a Single Course of Interferon-α2b in Patients with Histologically Mild Chronic Hepatitis C Annals of Internal Medicine. ,vol. 127, pp. 855- 865 ,(1997) , 10.7326/0003-4819-127-10-199711150-00001
E. Jenny Heathcote, Mitchell L. Shiffman, W. Graham E. Cooksley, Geoffrey M. Dusheiko, Samuel S. Lee, Luis Balart, Robert Reindollar, Rajender K. Reddy, Teresa L. Wright, Amy Lin, Joseph Hoffman, Jean De Pamphilis, Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. The New England Journal of Medicine. ,vol. 343, pp. 1673- 1680 ,(2000) , 10.1056/NEJM200012073432302
Lo Iacono, Castro, Diago, Moreno, Fernandez-Bermejo, Vega, García, Carbonell, Sanz, Borque, García-Buey, García-Monzón, Pedreira, Moreno-Otero, Interferon alfa‐2b plus ribavirin for chronic hepatitis C patients who have not responded to interferon monotherapy Alimentary Pharmacology & Therapeutics. ,vol. 14, pp. 463- 469 ,(2000) , 10.1046/J.1365-2036.2000.00713.X
G.R. Foster, Hepatitis C virus infection: quality of life and side effects of treatment Journal of Hepatology. ,vol. 31, pp. 250- 254 ,(1999) , 10.1016/S0168-8278(99)80411-5
Leonard B Seeff, Natural history of hepatitis C The American Journal of Medicine. ,vol. 107, pp. 10- 15 ,(1999) , 10.1016/S0002-9343(99)00374-5
Calleja, Albillos, Moreno-Otero, Rossi, Cacho, Domper, Yebra, Escartín, Sustained response to interferon-α or to interferon-α plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia Alimentary Pharmacology & Therapeutics. ,vol. 13, pp. 1179- 1186 ,(1999) , 10.1046/J.1365-2036.1999.00581.X
Jose Luis Calleja, Agustín Albillos, Guillermo Cacho, Jerónimo Iborra, Luis Abreu, Pedro Escartín, Interferon and prednisone therapy in chronic hepatitis C with non-organ-specific antibodies Journal of Hepatology. ,vol. 24, pp. 308- 312 ,(1996) , 10.1016/S0168-8278(96)80009-2
Nicholas C. Tassopoulos, Treatment of patients with chronic hepatitis C and normal ALT levels Journal of Hepatology. ,vol. 31, pp. 193- 196 ,(1999) , 10.1016/S0168-8278(99)80400-0